Literature DB >> 8862396

Effects of adenovirus E1A protein on interferon-signaling.

G T Leonard1, G C Sen.   

Abstract

We have previously shown that adenovirus E1A proteins can block interferon-alpha (IFN-alpha)-signalling. In the current study, we examined if the same is true for IFN-gamma signaling. Cotransfection experiments showed that both 289R and 243R forms of E1A could block the expression of an IFN-gamma-inducible reporter gene. Similarly, in an E1A-expressing HeLa cell line IFN-gamma failed to induce the synthesis of IRF-1 mRNA. This failure was due to a block in activation of the crucial trans-acting factor, GAF, which in turn was due to the lack of IFN-gamma-activated tyrosine phosphorylation of the STAT1 alpha protein in E1A-expressing cells. The above defect could be attributed to a reduced level of STAT1 alpha protein. The level of p48 protein, which is required for IFN-alpha signaling, was also lowered. However, the level of lak-1 protein, one of the tyrosine kinases necessary for both IFN-alpha and IFN-gamma signalling, was comparable in the E1A-expressing and the control cells. These results indicate that the observed inhibition of IFN signalling in E1A-expressing cells is a consequence of a lower abundance of the necessary trnas-acting factors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8862396     DOI: 10.1006/viro.1996.0503

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  36 in total

1.  Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells.

Authors:  B H Harcourt; A Sanchez; M K Offermann
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Differential role of Sp100 isoforms in interferon-mediated repression of herpes simplex virus type 1 immediate-early protein expression.

Authors:  Dmitri G Negorev; Olga V Vladimirova; Alexey Ivanov; Frank Rauscher; Gerd G Maul
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

3.  Human parainfluenza virus type 3 inhibits gamma interferon-induced major histocompatibility complex class II expression directly and by inducing alpha/beta interferon.

Authors:  J Gao; B P De; Y Han; S Choudhary; R Ransohoff; A K Banerjee
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

4.  Suppression of STAT-1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance.

Authors:  Shiyuan Hong; Kavi P Mehta; Laimonis A Laimins
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

5.  Modulation of major histocompatibility class II protein expression by varicella-zoster virus.

Authors:  A Abendroth; B Slobedman; E Lee; E Mellins; M Wallace; A M Arvin
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Characterization of the interaction between the interferon-induced protein P56 and the Int6 protein encoded by a locus of insertion of the mouse mammary tumor virus.

Authors:  J Guo; G C Sen
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

7.  Restoration of interferon responses of adenovirus E1A-expressing HT1080 cell lines by overexpression of p48 protein.

Authors:  G T Leonard; G C Sen
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

8.  Strategic attack on host cell gene expression during adenovirus infection.

Authors:  Hongxing Zhao; Fredrik Granberg; Ludmila Elfineh; Ulf Pettersson; Catharina Svensson
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  The type I interferon-alpha mediates a more severe neurological disease in the absence of the canonical signaling molecule interferon regulatory factor 9.

Authors:  Markus J Hofer; Wen Li; Sue Ling Lim; Iain L Campbell
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

10.  The role of mouse adenovirus type 1 early region 1A in acute and persistent infections in mice.

Authors:  K Smith; C C Brown; K R Spindler
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.